Targeting SphK2 Reverses Acquired Resistance of Regorafenib in Hepatocellular Carcinoma

Shi, WW; Zhang, S; Ma, D; Yan, DL; Zhang, G; Cao, Y; Wang, ZX; Wu, JH; Jiang, CP

Wang, ZX; Jiang, CP (corresponding author), Nanjing Univ, Dept Hepatobiliary Surg, Med Sch, Affiliated Drum Tower Hosp, Nanjing, Peoples R China.; Wang, ZX; Wu, JH; Jiang, CP (corresponding author), Nanjing Univ, Med Sch, Jiangsu Key Lab Mol Med, Nanjing, Peoples R China.; Wang, ZX; Jiang, CP (corresponding author), Nanjing Med Univ, Dept Hepatobiliary Surg, Drum Tower Clin Coll, Nanjing, Peoples R China.

FRONTIERS IN ONCOLOGY, 2020; 10 ():

Abstract

Background:Regorafenib is a second-line therapy drug used for advanced hepatocellular carcinoma (HCC). Unfortunately, the survival benefit of the pati......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索